Abstract
Given the established role of 90 kDa ribosomal S6 kinases (Rsk) in oncogenesis, and the promise of new Rsk-blocking cancer treatments, it is perhaps surprising that Rsk2-mediated inhibition of hyperplasia has now been demonstrated to occur in the arthritic synovium. Does this functional duality make Rsk2 a risky target for the treatment of rheumatoid arthritis?
| Original language | English |
|---|---|
| Pages (from-to) | 203-205 |
| Number of pages | 3 |
| Journal | Nature Reviews Rheumatology |
| Volume | 11 |
| Issue number | 4 |
| Early online date | 27 Jan 2015 |
| DOIs | |
| Publication status | Published - Apr 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Rheumatoid arthritis: The two faces of Rsk2 in hyperplastic disease'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver